Brokerages Set Sutro Biopharma, Inc. (NASDAQ:STRO) Target Price at $12.57

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have received an average rating of “Buy” from the seven research firms that are covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have covered the stock in the last year is $12.57.

STRO has been the topic of several recent research reports. JMP Securities reaffirmed a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a report on Wednesday, April 3rd. Piper Sandler restated an “overweight” rating and set a $11.00 target price (down from $12.00) on shares of Sutro Biopharma in a report on Wednesday, April 3rd. Wedbush restated an “outperform” rating and set a $8.00 price target on shares of Sutro Biopharma in a research report on Wednesday, April 3rd. HC Wainwright lowered their price objective on Sutro Biopharma from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Tuesday, March 26th. Finally, Truist Financial cut their target price on shares of Sutro Biopharma from $25.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, April 3rd.

Insider Transactions at Sutro Biopharma

In related news, insider Nicki Vasquez sold 12,185 shares of Sutro Biopharma stock in a transaction on Monday, January 29th. The shares were sold at an average price of $5.00, for a total value of $60,925.00. Following the sale, the insider now owns 12,803 shares in the company, valued at $64,015. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Sutro Biopharma

A number of institutional investors have recently bought and sold shares of the stock. American Century Companies Inc. boosted its position in Sutro Biopharma by 14.3% during the 1st quarter. American Century Companies Inc. now owns 14,656 shares of the company’s stock valued at $66,000 after acquiring an additional 1,833 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Sutro Biopharma by 9.9% in the fourth quarter. The Manufacturers Life Insurance Company now owns 20,667 shares of the company’s stock worth $167,000 after purchasing an additional 1,864 shares during the period. Principal Financial Group Inc. raised its holdings in Sutro Biopharma by 13.9% in the first quarter. Principal Financial Group Inc. now owns 15,348 shares of the company’s stock worth $71,000 after purchasing an additional 1,874 shares in the last quarter. American International Group Inc. lifted its position in Sutro Biopharma by 9.8% during the fourth quarter. American International Group Inc. now owns 25,500 shares of the company’s stock valued at $206,000 after buying an additional 2,273 shares during the period. Finally, Prudential Financial Inc. boosted its holdings in shares of Sutro Biopharma by 24.2% during the 1st quarter. Prudential Financial Inc. now owns 14,390 shares of the company’s stock valued at $66,000 after buying an additional 2,800 shares in the last quarter. 96.99% of the stock is owned by institutional investors.

Sutro Biopharma Price Performance

NASDAQ:STRO opened at $3.63 on Wednesday. The company has a market capitalization of $226.66 million, a price-to-earnings ratio of -2.04 and a beta of 0.95. Sutro Biopharma has a 1-year low of $2.01 and a 1-year high of $6.13. The business has a 50 day moving average of $4.47 and a 200 day moving average of $3.87.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.